Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

SFI prepares to resume dividend payments

5/12/23 SFIN

Nornickel continues to sell nickel through the port of Rotterdam

5/12/23 GMKN

Shareholders of KuibyshevAzot approved dividends for 2022

5/12/23 KAZT

Tattelecom reported for 3 months of 2023 by RAS

5/12/23 TTLK

Shareholders of Avangard Bank approved dividends for 2022

5/12/23 AVAN

Sistema acquired an office and hotel complex in Buryatia

5/11/23 AFKS

Board of Directors of Polyus recommended that dividends be paid for 2022

5/11/23 PLZL

Kamaz has sold a thousand flagship trucks since the beginning of the year

5/11/23 KMAZ

Ozon opened a second warehouse complex in Kazakhstan

5/11/23 OZON

JD.com reported 3 months of 2023

5/11/23 JD